Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Inclusion Criteria: * Male or female, aged 18 to 65 years old, inclusive * Willing and able to provide written informed consent. * Previously untreated HCV infection with HCV RNA \> 75,000 IU/mL at screening. * HCV genotype 1a or 1b. * Body mass index (BMI) between 18 and 38 kg/m2. * Willing and able to comply with the protocol and available to complete the study schedule of assessments. Exclusion Criteria: * Pregnant women or women who may wish to become pregnant during the course of the study. * Males and females of reproductive potential who are unwilling to use 2 forms of effective birth control throughout the duration of study treatment and for at least 6 months after the last dose of RBV. One method should include a condom with spermicide for males. Males must agree to refrain from sperm donation for at least 6 months after the last dose of RBV. * Evidence of infection or co-infection with a non-genotype 1 HCV strain. * Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV). * Lactating females